A Double-blind, Randomized, Placebo-controlled, Repeat Dose, 2-way Crossover Drug Interaction Study to Investigate the Pharmacokinetic and Pharmacodynamic Effects Following Administration of Fluticasone Furoate/GW642444M Inhalation Powder With Ketoconazole.

Trial Profile

A Double-blind, Randomized, Placebo-controlled, Repeat Dose, 2-way Crossover Drug Interaction Study to Investigate the Pharmacokinetic and Pharmacodynamic Effects Following Administration of Fluticasone Furoate/GW642444M Inhalation Powder With Ketoconazole.

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Jun 2017

At a glance

  • Drugs Vilanterol/fluticasone furoate (Primary) ; Ketoconazole
  • Indications Asthma; Chronic obstructive pulmonary disease
  • Focus Pharmacodynamics
  • Most Recent Events

    • 01 Nov 2012 Primary endpoint 'Cortisol-levels' has not been met.
    • 01 Nov 2012 Primary endpoint 'Potassium-levels' has been met.
    • 01 Nov 2012 Primary endpoint 'Heart-rate' has been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top